The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization

Vaccine

Volumn 28, Issue 8, 2010, Pages 1987-1996

  Masalova, Olga V ^a   Lesnova, Ekaterina I ^a   Pichugin, Alexei V ^b,c   Melnikova, Tatiana M ^c   Grabovetsky, Vadim V ^a   Petrakova, Natalia V ^a   Smirnova, Olga A ^d   Ivanov, Alexander V ^d   Zaberezhny, Alexei D ^a   Ataullakhanov, Ravshan I ^b,c   Isaguliants, Maria G ^a,e   Kushch, Alla A ^a  

^a D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^b INSTITUTE OF IMMUNOLOGY   (Russian Federation)

^c Immapharma Ltd   (Russian Federation)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^e SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Adjuvant; DNA immunization; HCV vaccine; Hepatitis C virus; Heterologous prime boost; Immunomax; Nonstructural protein 5A (NS5A); Promiscuous T cell epitopes

Indexed keywords

CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; IMMUNOMAX; INTERLEUKIN 2; NAKED DNA; NONSTRUCTURAL PROTEIN 5A; PEPTIDOGLYCAN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4 CD8 RATIO; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA IMMUNIZATION; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; EPITOPES; FEMALE; HEPATITIS C; HUMANS; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED DBA; PEPTIDOGLYCAN; RECOMBINANT PROTEINS; TH2 CELLS; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 76949095182     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.097     Document Type: Article

References (46)

1. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 7053 (2005) 946-952
2. Wintermeyer P., and Wands J.R. Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. J Gastroenterol 42 6 (2007) 424-432
3. Dreux M., and Cosset F.L. The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J Viral Hepat 14 Suppl. 1 (2007) 68-76
4. Zeisel M.B., Fafi-Kremer S., Fofana I., Barth H., Stoll-Keller F., Doffoel M., et al. Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 13 36 (2007) 4824-4830
5. Koziel M.J., Dudley D., Wong J.T., Dienstag J., Houghton M., Ralston R., et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 149 10 (1992) 3339-3344
6. Wong D.K., Dudley D.D., Afdhal N.H., Dienstag J., Rice C.M., Wang L., et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 160 3 (1998) 1479-1488
7. Cox A.L., Mosbruger T., Mao Q., Liu Z., Wang X.H., Yang H.C., et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201 11 (2005) 1741-1752
8. Frelin L., and Sallberg M. A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans. Genome Med 1 1 (2009) 15
9. Babiuk L.A., Pontarollo R., Babiuk S., Loehr B., and van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 21 7-8 (2003) 649-658
10. Abdulhaqq S.A., and Weiner D.B. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 42 1-3 (2008) 219-232
11. Greenland J.R., and Letvin N.L. Chemical adjuvants for plasmid DNA vaccines. Vaccine 25 19 (2007) 3731-3741
12. Bangari D.S., and Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24 7 (2006) 849-862
13. Tatsis N., Lasaro M.O., Lin S.W., Xiang Z.Q., Zhou D., Dimenna L., et al. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 182 10 (2009) 6587-6599
14. Doria-Rose N.A., and Haigwood N.L. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 31 3 (2003) 207-216
15. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccine 4 6 (2008) 449-452
16. Prud'homme G.J. DNA vaccination against tumors. J Gene Med 7 1 (2005) 3-17
17. Macdonald A., and Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85 Pt 9 (2004) 2485-2502
18. Penin F., Dubuisson J., Rey F.A., Moradpour D., and Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 39 1 (2004) 5-19
19. Appel N., Zayas M., Miller S., Krijnse-Locker J., Schaller T., Friebe P., et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 4 3 (2008) e1000035
20. Ivanov A.V., Tunitskaya V.L., Ivanova O.N., Mitkevich V.A., Prassolov V.S., Makarov A.A., et al. Hepatitis C virus NS5A protein modulates template selection by the RNA polymerase in in vitro system. FEBS Lett 583 2 (2009) 277-280
21. Masaki T., Suzuki R., Murakami K., Aizaki H., Ishii K., Murayama A., et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol (2008)
22. Tellinghuisen T.L., Foss K.L., and Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 4 3 (2008) e1000032
23. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96 1 (1995) 224-230
24. Pawlotsky J.M., Germanidis G., Neumann A.U., Pellerin M., Frainais P.O., and Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 72 4 (1998) 2795-2805
25. Reyes G.R. The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci 9 3 (2002) 187-197
26. Khabar K.S., Polyak S.J., and Hepatitis. C virus-host interactions: the NS5A protein and the interferon/chemokine systems. J Interferon Cytokine Res 22 10 (2002) 1005-1012
27. Park K.J., Choi S.H., Choi D.H., Park J.M., Yie S.W., Lee S.Y., et al. Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2. J Biol Chem 278 33 (2003) 30711-30718
28. Schmitz U., and Tan S.L. NS5A-from obscurity to new target for HCV therapy. Recent Pat Antiinfect Drug Discov 3 2 (2008) 77-92
29. Rechkina E.A., Denisova G.F., Masalova O.V., Lideman L.F., Denisov D.A., Lesnova E.I., et al. Epitope mapping of antigenic determinants of hepatitis C virus proteins by phage display. Mol Biol (Mosk) 40 2 (2006) 357-368
30. Rouille Y., Helle F., Delgrange D., Roingeard P., Voisset C., Blanchard E., et al. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 80 6 (2006) 2832-2841
31. Brazzoli M., Crotta S., Bianchi A., Bagnoli F., Monaghan P., Wileman T., et al. Intracellular accumulation of hepatitis C virus proteins in a human hepatoma cell line. J Hepatol 46 1 (2007) 53-59
32. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 7053 (2005) 961-966
33. Smyk-Pearson S., Tester I.A., Lezotte D., Sasaki A.W., Lewinsohn D.M., and Rosen H.R. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis 194 4 (2006) 454-463
34. Garmory H.S., Perkins S.D., Phillpotts R.J., and Titball R.W. DNA vaccines for biodefence. Adv Drug Deliv Rev 57 9 (2005) 1343-1361
35. Song M.K., Lee S.W., Suh Y.S., Lee K.J., and Sung Y.C. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J Virol 74 6 (2000) 2920-2925
36. Ghorbani M., Nass T., Azizi A., Soare C., Aucoin S., Giulivi A., et al. Comparison of antibody- and cell-mediated immune responses after intramuscular hepatitis C immunizations of BALB/c mice. Viral Immunol 18 4 (2005) 637-648
37. Yu H., Babiuk L.A., and van Drunen Littel-van den Hurk S. Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity. J Viral Hepat 15 6 (2008) 459-470
38. Inchauspe G., and Feinstone S. Development of a hepatitis C virus vaccine. Clin Liver Dis 7 1 (2003) 243-259 xi
39. Leroux-Roels G. Development of prophylactic and therapeutic vaccines against hepatitis C virus. Expert Rev Vaccines 4 3 (2005) 351-371
40. Lang K., and Weiner D.B. Immunotherapy for HCV infection: next steps. Expert Rev Vaccines 7 7 (2008) 915-923
41. Jiao X., Wang R.Y., Feng Z., Alter H.J., and Shih J.W. Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 37 2 (2003) 452-460
42. Matsui M., Moriya O., Belladonna M.L., Kamiya S., Lemonnier F.A., Yoshimoto T., et al. Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. J Virol 78 17 (2004) 9093-9104
43. Encke J., Bernardin J., Geib J., Barbakadze G., Bujdoso R., and Stremmel W. Genetic vaccination with Flt3-L and GM-CSF as adjuvants: enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. World J Gastroenterol 12 44 (2006) 7118-7125
44. Vajdy M., Selby M., Medina-Selby A., Coit D., Hall J., Tandeske L., et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 87 Pt 8 (2006) 2253-2262
45. Ataullakhanov RI, Pichugin AV, Khaitov RM (inventors). Preparation of a substance with immunostimulatory, antiviral and antibacterial activity. Substance obtained by this method and substance-based pharmaceutic compositions. Patent 2,195,308, Russia (27.12.2002).
46. Chadaev A.P., and Nurpisov A.M. Experimental and clinical study of immunomodulators Immunomax and Gepon in complex treatment of acute purulent surgical infection. Antibiot Khimioter 49 7 (2004) 9-16